Emergent BioSolutions (NYSE:EBS) Stock Rating Lowered by StockNews.com

Emergent BioSolutions (NYSE:EBS - Get Free Report) was downgraded by StockNews.com from a "buy" rating to a "hold" rating in a research note issued to investors on Saturday.

Several other research firms also recently weighed in on EBS. Benchmark lifted their price target on shares of Emergent BioSolutions from $8.00 to $12.00 and gave the company a "buy" rating in a research note on Thursday, November 7th. Rodman & Renshaw reaffirmed a "buy" rating and set a $16.00 target price on shares of Emergent BioSolutions in a research report on Friday, September 13th.

Emergent BioSolutions Trading Down 1.8 %

Shares of EBS traded down $0.15 during mid-day trading on Friday, reaching $8.27. 1,022,244 shares of the company's stock traded hands, compared to its average volume of 3,114,274. The company has a debt-to-equity ratio of 1.30, a current ratio of 2.88 and a quick ratio of 1.47. The stock's 50-day moving average is $9.21 and its two-hundred day moving average is $8.87. Emergent BioSolutions has a 12 month low of $1.42 and a 12 month high of $15.10. The stock has a market cap of $448.10 million, a P/E ratio of -2.02 and a beta of 1.59.

Institutional Investors Weigh In On Emergent BioSolutions

Several institutional investors have recently bought and sold shares of the company. SeaCrest Wealth Management LLC lifted its holdings in shares of Emergent BioSolutions by 3.2% during the 3rd quarter. SeaCrest Wealth Management LLC now owns 118,700 shares of the biopharmaceutical company's stock valued at $991,000 after purchasing an additional 3,705 shares during the last quarter. Meeder Asset Management Inc. acquired a new position in Emergent BioSolutions during the 2nd quarter valued at about $41,000. Verus Capital Partners LLC purchased a new stake in Emergent BioSolutions in the second quarter valued at about $68,000. Stifel Financial Corp acquired a new stake in Emergent BioSolutions in the third quarter worth about $96,000. Finally, FORA Capital LLC purchased a new stake in shares of Emergent BioSolutions during the third quarter worth about $103,000. 78.40% of the stock is currently owned by institutional investors and hedge funds.

Emergent BioSolutions Company Profile

Emergent BioSolutions Inc, a life sciences company, provides preparedness and response solutions for accidental, deliberate, and naturally occurring public health threats in the United States. The company offers NARCAN Nasal Spray for the emergency treatment of known or suspected opioid overdose; Vaxchora vaccine for the prevention of cholera; Vivotif vaccine for oral administration for the prevention of typhoid fever; Anthrasil for the treatment of inhalational anthrax; BioThrax, an anthrax vaccine; CYFENDUS for post-exposure prophylaxis of disease following suspected or confirmed exposure to Bacillus anthracis; and Raxibacumab injection for the treatment and prophylaxis of inhalational anthrax.